NASDAQ:MXCT
Maxcyte, Inc.
Maxcyte, Inc.'s revenue fell 14.5% in fiscal 2025 to $33.0M while operating margin fell to −157.1%, its lowest in 7 years. Free cash flow was −$36.2M, −109.5% of revenue, and the diluted share count rose 1.5%.Summary generated from Maxcyte, Inc.'s SEC filings. Latest annual report filed Mar 25, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$33.0M
Revenue growth−14.5%
Revenue, 5-yr CAGR+4.8%
Gross margin81.2%
Operating margin−157.1%
Net margin−135.1%
ROICn/a
Return on equity−23.6%
Debt / equityn/a
Free cash flow−$36.2M
FCF margin−109.5%
Share count change+1.5%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 34 | 44 | 41 | 39 | 33 |
| Operating income | −18 | −27 | −48 | −51 | −52 |
| Net income | −19 | −24 | −38 | −41 | −45 |
| Free cash flow | −15 | −33 | −25 | −29 | −36 |
Recent filings
- 10-QQuarterly report for the period ended Jun 30, 2026
Aug 13, 2026 - 8-KResults of operations and financial condition
Aug 12, 2026 - 4Insider transaction report
Jun 22, 2026 - 4Insider transaction report
Jun 22, 2026 - 8-KResults of a shareholder vote
Jun 17, 2026 - 8-KNotice of delisting or listing-rule failure
Jun 16, 2026 - 10-QQuarterly report for the period ended Mar 31, 2026
May 13, 2026 - 8-KResults of operations and financial condition
May 12, 2026